PCSK9 억제제 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)
PCSK9 Inhibitor Market (Drug Type: Alirocumab, Evolocumab, Inclisiran, and Tafolecimab; and Modality: Fully-humanized Monoclonal Antibodies and siRNA) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1552737
리서치사:Transparency Market Research
발행일:2024년 07월
페이지 정보:영문 134 Pages
라이선스 & 가격 (부가세 별도)
한글목차
PCSK9 억제제 시장 - 조사 범위
TMR의 조사 보고서 'PCSK9 억제제 세계 시장'은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회에 대해서도 조사 있습니다. 본 보고서는 2024년을 기준년, 2034년을 예측년으로, 2018년부터 2034년까지 세계 PCSK9 억제제 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 PCSK9 억제제 시장의 복합 연간 성장률(CAGR%)도 제공합니다.
이 보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서 분석가는 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체와의 인터뷰를 실시했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참조하여 PCSK9 억제제 시장을 추찰했습니다.
시장 현황
2023년 시장 규모
17억 달러
2034년 시장 규모
93억 달러
CAGR
16.9%
이 보고서는 세계 PCSK9 억제제 시장 경쟁 구도를 조사했습니다. 세계 PCSK9 억제제 시장에서 사업을 전개하는 주요 기업이 확인되고 각 기업은 다양한 속성으로 프로파일 링됩니다. 기업 개요, 재무상황, 최근 동향, SWOT 등이 본 보고서에서 소개된 세계 PCSK9 억제제 시장에서 기업의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약: 세계 시장
제4장 시장 개요
소개
개요
시장 역학
세계 시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 M&A
COVID-19에 의한 산업에 대한 영향
제6장 세계 시장 분석과 예측 : 약제유형별
소개 및 정의
주요 조사 결과· 발전
시장 매출 예측 : 약제유형별, 2020-2034년
알리로쿠맙
에볼로쿠맙
잉크리실란
타포레시맙
시장의 매력 : 약제유형별
제7장 세계 시장 분석과 예측 : 모달리티별
소개 및 정의
주요 조사 결과· 발전
시장 매출 예측 : 모달리티별, 2020-2034년
완전 인간화 단클론항체
siRNA
시장의 매력 : 모달리티별
제8장 세계 시장 분석과 예측 : 적응증별
소개 및 정의
주요 조사 결과· 발전
시장 매출 예측 :적응증별, 2020-2034년
원발성 고지혈증
가족성 고콜레스테롤혈증
기타
시장의 매력: 적응증별
제9장 세계 시장 분석과 예측 : 유통 채널별
소개 및 정의
주요 조사 결과· 발전
시장 매출 예측 : 유통 채널별, 2020-2034년
병원 약국
소매 약국
온라인 약국
시장의 매력 : 유통 채널별
제10장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 :지역별, 2020-2034년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 : 지역별
제11장 북미 시장 분석과 예측
제12장 유럽 시장 분석과 예측
제13장 아시아태평양 시장 분석과 예측
제14장 라틴아메리카 시장 분석과 예측
제15장 중동 및 아프리카 시장 분석과 예측
제16장 경쟁 구도
시장기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
시장 점유율 분석 : 기업별(2023)
기업 프로파일
Novartis AG
Regeneron Pharmaceuticals
Amgen Inc.
Innovent Bio
LIB Therapeutics
Shanghai Junshi Biosciences Co., Ltd.
Merck & Co., Inc.
AstraZeneca plc
JHS
영문 목차
영문목차
PCSK9 Inhibitor Market - Scope of Report
TMR's report on the global PCSK9 inhibitor market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global PCSK9 inhibitor market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global PCSK9 inhibitor market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the PCSK9 inhibitor market.
Market Snapshot
Market Value in 2023
US$ 1.7 Bn
Market Value in 2034
US$ 9.3 Bn
CAGR
16.9%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global PCSK9 inhibitor market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global PCSK9 inhibitor market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global PCSK9 inhibitor market.
The report delves into the competitive landscape of the global PCSK9 inhibitor market. Key players operating in the global PCSK9 inhibitor market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global PCSK9 inhibitor market profiled in this report.
Key Questions Answered in Global PCSK9 inhibitor Market Report:
What is the sales/revenue generated by PCSK9 inhibitor across all regions during the forecast period?
What are the opportunities in the global PCSK9 inhibitor market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
PCSK9 Inhibitor Market - Research Objectives and Research Approach
The comprehensive report on the global PCSK9 inhibitor market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global PCSK9 inhibitor market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global PCSK9 inhibitor market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global PCSK9 Inhibitors Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global PCSK9 Inhibitors Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global PCSK9 Inhibitors Market Analysis and Forecast, by Drug Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2020-2034
6.3.1. Alirocumab
6.3.2. Evolocumab
6.3.3. Inclisiran
6.3.4. Tafolecimab
6.4. Market Attractiveness, by Drug Type
7. Global PCSK9 Inhibitors Market Analysis and Forecast, by Modality
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Modality, 2020-2034
7.3.1. Fully-humanized Monoclonal Antibodies
7.3.2. siRNA
7.4. Market Attractiveness, by Modality
8. Global PCSK9 Inhibitors Market Analysis and Forecast, by Indication
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication, 2020-2034
8.3.1. Primary Hyperlipidemia
8.3.2. Familial Hyper Cholesterolemia
8.3.3. Other Cardiovascular Disorders
8.4. Market Attractiveness, by Indication
9. Global PCSK9 Inhibitors Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global PCSK9 Inhibitors Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America PCSK9 Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2020-2034
11.2.1. Alirocumab
11.2.2. Evolocumab
11.2.3. Inclisiran
11.2.4. Tafolecimab
11.3. Market Attractiveness, by Drug Type
11.4. Market Value Forecast, by Modality, 2020-2034
11.4.1. Fully-humanized Monoclonal Antibodies
11.4.2. siRNA
11.5. Market Attractiveness, by Modality
11.6. Market Value Forecast, by Indication, 2020-2034
11.6.1. Primary Hyperlipidemia
11.6.2. Familial Hyper Cholesterolemia
11.6.3. Other Cardiovascular Disorders
11.7. Market Attractiveness, by Indication
11.8. Market Value Forecast, by Distribution Channel, 2020-2034
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Drug Type
11.11.2. By Modality
11.11.3. By Indication
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe PCSK9 Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2020-2034
12.2.1. Alirocumab
12.2.2. Evolocumab
12.2.3. Inclisiran
12.2.4. Tafolecimab
12.3. Market Attractiveness, by Drug Type
12.4. Market Value Forecast, by Modality, 2020-2034
12.4.1. Fully-humanized Monoclonal Antibodies
12.4.2. siRNA
12.5. Market Attractiveness, by Modality
12.6. Market Value Forecast, by Indication, 2020-2034
12.6.1. Primary Hyperlipidemia
12.6.2. Familial Hyper Cholesterolemia
12.6.3. Other Cardiovascular Disorders
12.7. Market Attractiveness, by Indication
12.8. Market Value Forecast, by Distribution Channel, 2020-2034
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Drug Type
12.11.2. By Modality
12.11.3. By Indication
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific PCSK9 Inhibitors Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2020-2034
13.2.1. Alirocumab
13.2.2. Evolocumab
13.2.3. Inclisiran
13.2.4. Tafolecimab
13.3. Market Attractiveness, by Drug Type
13.4. Market Value Forecast, by Modality, 2020-2034
13.4.1. Fully-humanized Monoclonal Antibodies
13.4.2. siRNA
13.5. Market Attractiveness, by Modality
13.6. Market Value Forecast, by Indication, 2020-2034
13.6.1. Primary Hyperlipidemia
13.6.2. Familial Hyper Cholesterolemia
13.6.3. Other Cardiovascular Disorders
13.7. Market Attractiveness, by Indication
13.8. Market Value Forecast, by Distribution Channel, 2020-2034
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Drug Type
13.11.2. By Modality
13.11.3. By Indication
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America PCSK9 Inhibitors Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2020-2034
14.2.1. Alirocumab
14.2.2. Evolocumab
14.2.3. Inclisiran
14.2.4. Tafolecimab
14.3. Market Attractiveness, by Drug Type
14.4. Market Value Forecast, by Modality, 2020-2034
14.4.1. Fully-humanized Monoclonal Antibodies
14.4.2. siRNA
14.5. Market Attractiveness, by Modality
14.6. Market Value Forecast, by Indication, 2020-2034
14.6.1. Primary Hyperlipidemia
14.6.2. Familial Hyper Cholesterolemia
14.6.3. Other Cardiovascular Disorders
14.7. Market Attractiveness, by Indication
14.8. Market Value Forecast, by Distribution Channel, 2020-2034
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Drug Type
14.11.2. By Modality
14.11.3. By Indication
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa PCSK9 Inhibitors Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Type, 2020-2034
15.2.1. Alirocumab
15.2.2. Evolocumab
15.2.3. Inclisiran
15.2.4. Tafolecimab
15.3. Market Attractiveness, by Drug Type
15.4. Market Value Forecast, by Modality, 2020-2034
15.4.1. Fully-humanized Monoclonal Antibodies
15.4.2. siRNA
15.5. Market Attractiveness, by Modality
15.6. Market Value Forecast, by Indication, 2020-2034
15.6.1. Primary Hyperlipidemia
15.6.2. Familial Hyper Cholesterolemia
15.6.3. Other Cardiovascular Disorders
15.7. Market Attractiveness, by Indication
15.8. Market Value Forecast, by Distribution Channel, 2020-2034
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Drug Type
15.11.2. By Modality
15.11.3. By Indication
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Novartis AG
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Regeneron Pharmaceuticals
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Amgen Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Innovent Bio
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. LIB Therapeutics
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Shanghai Junshi Biosciences Co., Ltd.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Merck & Co., Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. AstraZeneca plc
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
